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Summary
Although race, in and of itself, is not a relevant biologic variable, racial differences in disease characteristics
and outcomes have been reported in many malignancies, including lung cancer. The lung cancer incidence
rate in blacks has been consistently higher than that in whites for many years. This racial disparity is seen
primarily in men and is significantly greater in younger age groups. The reason for higher lung cancer
incidence rates in blacks remains unclear, but racial differences in smoking habits, socioeconomic variables,
and the metabolism of tobacco carcinogens may all play an important role. Blacks are also more likely than
whites to present with squamous cell carcinoma and with advanced-stage disease. A significant racial
difference in survival rates has developed over the past 30 years, with a poorer prognosis noted in black
patients, particularly those with local- and regional-stage disease. This disparity appears to be due to a lack
of improvement in the survival of black patients with lung cancer, but the biological and/or societal basis
for racial variations in survival have not been determined. In summary, significant racial differences exist in
lung cancer incidence and survival rates. Further research is required to determine the factors responsible
for these differences and to develop effective preventative and therapeutic interventions that will impact
favorably on the incidence and prognosis of this disease.
Introduction
Lung cancer is currently the most common cause
of cancer-related mortality for both men and
women in the US, and is likely to remain so
despite recent declines in lung cancer mortality
rates [1]. During the last century, lung cancer
evolved from a rare pathologic entity to a major
public health problem due to the dramatic
increase in the prevalence of cigarette smoking.
On the positive side, the strong association
between tobacco use and lung cancer provides
the opportunity for relatively straight-forward
public health measures to have a major long-
term impact on the incidence of this disease. In
addition, the magnitude of the problem will allow
for small improvements in the treatment of lung
cancer to translate into major public health
benefits.
For many years, race was considered an
important biologic factor that could affect both
the development and outcome of many diseases.
However, advances in genetics and the social
sciences have demonstrated that race, in and of
itself, is usually not a relevant biologic variable [2].
It is now clear that race is an imperfect and
complex variable with strong socioeconomic asso-
ciations and questionable biological significance.
Nonetheless, the analysis of racial differences in a
diseased cohort can identify important clinico-
pathologic variations that may lead to useful
interventions aimed at the specific needs of a
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targeted sub-population [3]. Racial differences in
disease characteristics and outcomes are well
recognized for many malignancies, including lung
cancer [4–6]. In recent years, the recognition of
higher incidence rates and lower survival rates for
lung cancer in blacks compared to whites has
received increasing public attention [7]. These
racial differences have been attributed to a variety
of factors, including smoking habits, socioeco-
nomic status, genetic susceptibility, occupational
exposure, diet, and treatment.
In order to further characterize racial variations
in the clinicopathologic features of lung cancer, we
previously reported an analysis of data collected
by the metropolitan Detroit Surveillance, Epide-
miology and End Results (SEER) registry from
1973–1998 [8]. Of the 48,318 patients with primary
lung cancer included in our report, 23% were
black, 34% were female, and 8% were under 50
years of age at diagnosis. This review will consider
the racial disparities in incidence, histology, stage,
and survival that have been observed in patient
with lung cancer and will offer some insight into
the potential reasons behind these differences.
Incidence
Over the last 40 years, lung cancer incidence rates
have been consistently higher in blacks than in
whites [1,9]. This difference is gender specific, with
incidence rates in black men being reported as 35–
50% higher than those in white men, while the
incidence rates in women of both races have been
similar [8,10]. In our analysis of the metropolitan
Detroit SEER registry, the age-adjusted incidence
rates (per 100,000 person-years) were 85.8 in black
men, 62.7 in white men, 29.6 in black women, and
27.1 in white women (Figure 1) [8]. Since the early
1980s, lung cancer incidence rates have been
decreasing in men of both races, but this decline
has been greater in black men [8]. Unfortunately,
incidence rates in women of both races have
continued to rise, though recent data suggests that
they may be reaching a plateau.
The degree of the racial differences in lung
cancer incidence also varies with age, with greater
disparity noted in younger population groups
[8,11]. In our analysis of the metropolitan Detroit
SEER registry, lung cancer incidence in younger
black men (age < 50 years) was over 2-fold higher
than in younger white men ð10.4/100,000 vs. 5.1/
100,000, p< 0.05Þ. Despite an overall decrease in
the incidence of lung cancer in men of both races,
the racial disparity in younger men continued to
increase throughout the study period [8]. Such age-
related variations in incidence rates between blacks
and whites have also been reported in other
cancers, suggesting significant racially associated
differences in susceptibility to various carcinogens.
The higher rate of lung cancer in young black men
is surprising considering that blacks generally start
smoking at a later age and smoke fewer cigarettes
per day. It is possible non-smoking-related factors,
such as other environmental exposures or socio-
economic status, may have greater impact in
younger individuals.
Tobacco use
Racial differences in smoking patterns have been
extensively evaluated. Smoking prevalence rates of
blacks and whites were similar up until the 1960s
when significant differences began to emerge,
primarily in men [9,12]. However, these disparities
in smoking prevalence rates cannot fully explain
the racial differences in lung cancer incidence rates
since there was substantial temporal overlap in
their emergence. In addition, the magnitude of the
racial difference in smoking prevalence (1960s:
black 43%, white 40%; 1980s: black 34%, white
29%; 1998: black 29%, whites 27%) is substantially
smaller than that in lung cancer incidence [12,13].
In addition to the differences in prevalence,
smoking patterns and habits have also been shown
to vary along racial lines. Black smokers tend to
start smoking at a later age and smoke fewer
cigarettes per day, but are less likely to quit [12,14].
In 1987, the quit rate was 32% for black smokers
and 47% for whites [12]. Thus, blacks are more
likely to be long-term smokers, potentially increas-
ing their risk of developing tobacco-related dis-
orders, such as lung cancer. Since smoking
initiation rates are similar in blacks and whites, it
has been proposed that the lower quit rate in
blacks is the primary reason for the racial
differences noted in smoking prevalence rates.
The use of mentholated cigarettes is much more
common in blacks, with 70–80% of black smokers
and only 20–30% of the white smokers regularly
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smoking mentholated cigarettes [15]. It has been
hypothesized that the use of mentholated cigar-
ettes can increase the risk of lung cancer since they
have higher tar content than non-mentholated
cigarettes [16], generate higher levels of known
carcinogens [17], facilitate the absorption of
carbon monoxide [18], and limit ventilation lead-
ing to greater pulmonary retention of tobacco
smoke [19,20]. Two studies have suggested an
association between mentholated cigarette use and
higher lung cancer risk in men, although the
results of population-based studies remain incon-
clusive [21–23]. Overall, blacks also smoke cigar-
ettes with higher tar and nicotine content,
potentially enhancing dependence and the risk of
lung cancer [14,24].
Socioeconomic factors
The importance of socioeconomic variables as
cancer risk factors and prognostic markers has
been recognized by many investigators. Socio-
economic factors, such as lower income and
education level, are associated with a higher risk
of lung cancer and a higher overall cancer
mortality rate [25,26]. Prior analyses of the
SEER registry have found that most black cancer
patients live in high population density areas with
lower median incomes and education levels, and
that age-adjusted lung cancer incidence rates are
inversely related to family income and level of
education [27–29]. In addition, the lung cancer
incidence rate in blacks was slightly lower than in
whites after adjustment for socioeconomic status,
suggesting that these factors play an important
role in determining the high lung cancer risk
observed in the black community.
Socioeconomic status correlates with a variety
of lifestyle factors that may impact on lung
carcinogenesis, such as tobacco and alcohol use,
diet, and exposure to occupational and environ-
mental carcinogens [30]. Lower socioeconomic
status is associated with higher smoking preva-
lence and nicotine-dependence rates, greater use of
non-filter, high-tar cigarettes, and a lower quit rate
[6,12,28]. With regard to diet, the Health and
Nutrition Examination Survey reported that the
diet of American blacks contains more fat and
fewer fruits and vegetables, dietary factors that are
known to be associated with a higher risk of lung
cancer, than that of whites [31–33]. In a case-
control study, Swanson and colleagues noted that
whites ate more raw vegetables, while blacks ate
more preserved and processed meat with greater
carcinogenic potential [34].
Blacks also may have greater occupational and
environmental carcinogen exposure and greater
susceptibility for the development of lung cancer
Figure 1. Age-adjusted incidence rates of lung cancer by race and gender in metropolitan Detroit (1973–1998). (Reprinted from
Gadgeel et al. [8]).
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after such exposure than whites. A case-control
study by Muscat and colleagues suggested that
occupational exposure to lung carcinogens may be
more common in blacks than in whites and that
exposure to asbestos and coal significantly
increased the risk of lung cancer in black males
[35]. Swanson and colleagues evaluated the rela-
tionship between race, occupation and lung cancer
risk in metropolitan Detroit, and reported that
among occupations associated with an increased
risk of lung cancer, the risk in black males was
consistently greater than in white males [36].
Genetic and metabolic pathways
Although recent genetic studies have suggested
that race does not have general biological rele-
vance, the prevalence of a number genetic varia-
tions (polymorphisms) in genes that may affect the
susceptibility to tobacco carcinogens have been
found to vary significantly along racial lines. Thus
far, genetic studies have primarily focused on
genes encoding for enzymes that are involved in
the metabolism of environmental and tobacco-
related carcinogens, such as the cytochrome P450
family members CYP1A1, involved in carcino-
genic activation of hydrocarbons, CYP2C9,
involved in the activation of benzo[a]pyrene, and
CYP2E1, involved in the metabolic activation of
tobacco-specific nitrosamines [37–40]. Many stu-
dies have reported on the occurrence of various
polymorphisms of these genes in racial subgroups
and their association with lung cancer incidence.
These reports have frequently yielded conflicting
data and are confounded by the general lack of
knowledge regarding the functional consequences,
if any, of the evaluated polymporphisms. In
general, a consistent association between genetic
polymorphisms in metabolic enzymes and the
incidence of lung cancer in any racial subpopula-
tion has not been clearly demonstrated.
However, there do appear to be reproducible
racial differences in the intake and metabolism of
nicotine. Perez-Stable and colleagues reported that
black smokers had higher serum levels of cotinine,
a metabolite of nicotine, despite similar daily
cigarette consumption, and a 30% higher intake
of nicotine per cigarette than white smokers [41].
These differences may be due to genetic variations
in metabolic enzymes, more frequent use of
mentholated cigarettes in blacks, or habitual
differences in the frequency or depth of smoke
inhalation. Similar results have been reported from
a national study of over 7,000 smokers [42]. These
findings may help to explain both the low quit rate
and the high incidence of lung cancer consistently
observed in blacks.
Considering all of the aforementioned data, it is
likely that the cause of the observed racial
differences in lung cancer incidence is multi-
factorial, involving a wide variety of tobacco-
related, socioeconomic, and genetic factors.
Histology and stage
Over the last 15 years, adenocarcinoma has
replaced squamous cell carcinoma as the predo-
minant histologic subtype of lung cancer in the US
[4]. This histologic shift has been observed in both
blacks and whites, and appears to be temporally
associated with the introduction of filter-tip
cigarettes with lower tar and nicotine content
[43]. It is speculated that filter-tip cigarettes allow
deeper inhalation of tobacco smoke, increasing the
carcinogen exposure of peripheral airways in
which adenocarcinoma arises. In our analysis of
the metropolitan Detroit SEER registry, the
incidence of squamous cell carcinoma declined
more in blacks than in whites during the study
period [8]. However, the overall incidence of
squamous cell carcinoma remained higher in
both black males and females, perhaps due to
greater use of non-filtered, high-tar, high-nicotine
cigarettes by blacks or the existence of more long-
term black smokers [14,44].
Stage of disease at presentation is the most
important prognostic factor in lung cancer.
Unfortunately, most patients present with locally
advanced or metastatic disease, accounting for the
high overall mortality rate associated with this
disease. Significant racial differences have been
observed in the stage of lung cancer at presenta-
tion, with blacks exhibiting a higher incidence of
advanced-stage disease than whites [8,45,46]. Over
the past 25 years, the proportion of all patients
with advanced-stage disease has increased, pri-
marily due to improvements in the sensitivity and
availability of state-of-the-art staging modalities.
Over the same period of time, the racial disparity
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in stage at presentation also increased, with the
proportion of patients with distant-stage disease
increasing from 44% to 53% in blacks and from
42% to 48% in whites [8]. In addition, the incidence
rate for potentially curable early-stage disease
declined in blacks (11.6 to 9.7/100,000), but
increased slightly in whites (8.9 to 9.2/100,000).
Racial differences in health care access and
attitudes may account for some of this racial
disparity in stage.
Therapy and survival
The overall 5-year survival rate for patients with
lung cancer has increased from 8% to 14% over the
past 30 years. Numerous analyzes have demon-
strated that survival rates for black patients with
lung cancer are lower than for white patients [4]. In
our study of the metropolitan Detroit SEER
registry, we noted that the survival gap between
black and white lung cancer patients has widened
significantly since the mid-1980s (Figure 2) [8].
From 1973–1985, overall 5-year survival was
11.3% in blacks and 12.7% in whites ðp ¼ 0.067Þ,
while from 1986–1998, it was 11.5% in blacks and
16.5% in whites ðp< 0.0001Þ. It appears that this
gap is primarily due to modest improvements in
the overall survival rates of white patients with
local- and regional-stage disease, while the survival
rates of black patients have remained relatively
unchanged over the last 25 years. This trend has
resulted in stage-specific 5-year survival rates that
are significantly lower for black patients with
local-stage ð37.1% vs. 45.3%, p ¼ 0.0001Þ and
regional-stage ð14.8% vs. 23.7%, p< 0.0001Þ dis-
ease [8].
Survival in lung cancer is influenced by multiple
factors, including stage of disease, performance
status, the presence of co-morbid conditions, and
access to health care. Some of these factors may
have particular importance in the treatment of
regional-stage disease, where the greatest change
in black versus white survival has occurred. Since
the mid-1980s, the widespread use of combined
modality therapy has led to modest improvement
in the survival of patients with regional-stage lung
cancer. This type of treatment is expensive and
logistically complicated, and requires a good
performance status, all of which may impede the
availability of combined modality therapy to
patients with lower socioeconomic status. Several
factors, including lower socioeconomic status and
increased rates of long-term smoking, can be
associated with a greater probability of significant
co-morbid conditions and poorer performance
Figure 2. Relative 2- and 5-year survival rates of lung cancer patients at all stages by race in metropolitan Detroit (1973–1997,
calculated by 3-year moving average). (Reprinted from Gadgeel et al. [8].)
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status in black patients with lung cancer. Due to
the potential toxicity of aggressive anticancer
therapy, the presence of co-morbid conditions
can have a substantial impact on treatment
decisions and prognosis.
Several investigators have noted that white
patients undergo significantly more cancer-direc-
ted surgery than blacks [45]. A recent study
reported that the 5-year survival difference
between elderly black and white patients (26.4%
vs. 34.1%) with early-stage lung cancer was
associated with lower surgical resection rates in
black patients (64% vs. 77%) despite the lack of
any racial difference in co-morbidity [47]. Of
particular interest, there was no difference in the
survival of black and white patients who under-
went surgery. Lack of personal resources and
jaded personal perceptions of the health care
system can limit access to appropriate health
care, thereby preventing early diagnosis and
appropriate treatment of many diseases, including
lung cancer. In the US, a greater proportion of the
black population is uninsured and many blacks
exhibit profound distrust of the current health care
establishment [48–50]. In a Veterans’ Administra-
tion study evaluating outcomes of veterans with
advanced lung or colon cancer, the survival of
patients of both races was similar despite lower
overall socioeconomic status in black patients,
suggesting that equal access to comparable health
care results in equal outcomes [51].
Conclusions
Studies on the biological impact of race must be
interpreted cautiously due to the complex nature
of the race variable and the exclusion of many
relevant socioeconomic parameters from most
disease-based databases. Overall, significant
declines in the incidence and mortality of lung
cancer in select subsets of the population are
encouraging. However, in the last two decades
several disturbing racial trends have developed,
including the lower relative decline in lung cancer
incidence in younger black males, the greater trend
toward advanced-stage disease blacks, and the
widening racial disparity in survival. These racial
trends are likely due to the interaction of a variety
of lifestyle, socioeconomic, and genetic factors. An
appropriate understanding of these differences is
an important step in the development and
implementation of more effective preventive and
therapeutic strategies that will have a positive
impact on all patients with lung cancer.
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